JMP Securities Issues Positive Forecast for KalVista Pharmaceuticals (NASDAQ:KALV) Stock Price

KalVista Pharmaceuticals (NASDAQ:KALV - Get Free Report) had its price objective upped by equities researchers at JMP Securities from $19.00 to $27.00 in a research note issued to investors on Tuesday,Benzinga reports. The firm presently has a "market outperform" rating on the specialty pharmaceutical company's stock. JMP Securities' target price indicates a potential upside of 85.95% from the company's current price.

Several other research analysts have also weighed in on KALV. HC Wainwright lifted their target price on KalVista Pharmaceuticals from $20.00 to $27.00 and gave the stock a "buy" rating in a report on Tuesday. Jones Trading reiterated a "buy" rating and set a $30.00 target price on shares of KalVista Pharmaceuticals in a report on Wednesday, March 26th. Needham & Company LLC restated a "buy" rating and issued a $28.00 price target on shares of KalVista Pharmaceuticals in a report on Tuesday, April 8th. Finally, Leerink Partners boosted their price target on KalVista Pharmaceuticals from $18.00 to $20.00 and gave the company an "outperform" rating in a report on Monday. Eight equities research analysts have rated the stock with a buy rating and one has given a strong buy rating to the company. Based on data from MarketBeat.com, KalVista Pharmaceuticals currently has an average rating of "Buy" and a consensus target price of $26.29.

KalVista Pharmaceuticals Stock Performance

KALV stock traded down $0.99 during midday trading on Tuesday, hitting $14.52. 2,085,829 shares of the company's stock were exchanged, compared to its average volume of 572,165. The stock's fifty day moving average price is $12.57 and its 200-day moving average price is $11.23. The company has a market cap of $721.93 million, a PE ratio of -3.93 and a beta of -0.04. KalVista Pharmaceuticals has a one year low of $7.30 and a one year high of $16.32.

KalVista Pharmaceuticals (NASDAQ:KALV - Get Free Report) last posted its earnings results on Thursday, July 10th. The specialty pharmaceutical company reported ($3.69) earnings per share for the quarter, missing the consensus estimate of ($0.83) by ($2.86). During the same period in the previous year, the company posted ($1.07) earnings per share. On average, analysts expect that KalVista Pharmaceuticals will post -3.56 EPS for the current year.

Insider Transactions at KalVista Pharmaceuticals

In other news, CEO Benjamin L. Palleiko sold 32,979 shares of the business's stock in a transaction dated Wednesday, July 9th. The stock was sold at an average price of $15.69, for a total value of $517,440.51. Following the sale, the chief executive officer directly owned 369,595 shares in the company, valued at $5,798,945.55. The trade was a 8.19% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. Also, insider Paul K. Audhya sold 2,776 shares of KalVista Pharmaceuticals stock in a transaction dated Monday, May 19th. The shares were sold at an average price of $11.84, for a total value of $32,867.84. Following the completion of the sale, the insider directly owned 106,611 shares in the company, valued at approximately $1,262,274.24. This represents a 2.54% decrease in their position. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 48,878 shares of company stock worth $723,617. Corporate insiders own 10.50% of the company's stock.

Institutional Trading of KalVista Pharmaceuticals

A number of hedge funds and other institutional investors have recently modified their holdings of the stock. Goldman Sachs Group Inc. increased its position in shares of KalVista Pharmaceuticals by 3.7% in the first quarter. Goldman Sachs Group Inc. now owns 339,936 shares of the specialty pharmaceutical company's stock valued at $3,923,000 after acquiring an additional 12,263 shares during the last quarter. Rhumbline Advisers increased its position in shares of KalVista Pharmaceuticals by 3.4% in the first quarter. Rhumbline Advisers now owns 52,918 shares of the specialty pharmaceutical company's stock valued at $611,000 after acquiring an additional 1,762 shares during the last quarter. Woodline Partners LP increased its position in shares of KalVista Pharmaceuticals by 25.5% in the first quarter. Woodline Partners LP now owns 1,617,469 shares of the specialty pharmaceutical company's stock valued at $18,666,000 after acquiring an additional 329,068 shares during the last quarter. Parkman Healthcare Partners LLC acquired a new stake in shares of KalVista Pharmaceuticals in the first quarter valued at about $8,698,000. Finally, MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. increased its position in shares of KalVista Pharmaceuticals by 13.7% in the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 24,325 shares of the specialty pharmaceutical company's stock valued at $281,000 after acquiring an additional 2,939 shares during the last quarter.

About KalVista Pharmaceuticals

KalVista Pharmaceuticals, Inc, a clinical stage pharmaceutical company, engages in the discovery, development, and commercialization of drug therapies inhibitors for diseases with unmet needs. The company's product candidate is Sebetralstat, a small molecule plasma kallikrein inhibitor targeting the disease of hereditary angioedema (HAE).